Cardiac involvement in genotype-positive Fabry disease patients assessed by cardiovascular MR

Heart

Volumn 102, Issue 4, 2016, Pages 298-302

  Kozor, Rebecca ^a,b,c   Grieve, Stuart M ^a,b,d   Tchan, Michel C ^b,e   Callaghan, Fraser ^b   Hamilton Craig, Christian ^f,g   Denaro, Charles ^g,h   Moon, James C ⁱ   Figtree, Gemma A ^a,b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

^f THE PRINCE CHARLES HOSPITAL   (Australia)

^g UNIVERSITY OF QUEENSLAND   (Australia)

^h ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

ⁱ ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE ASSESSMENT; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; GENOTYPE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART PAPILLARY MUSCLE; HUMAN; LEFT VENTRICULAR MASS INDEX; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; CARDIOMYOPATHIES; CINE MAGNETIC RESONANCE IMAGING; CLINICAL TRIAL; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MULTICENTER STUDY; NEW SOUTH WALES; PHENOTYPE; PREDICTIVE VALUE; QUEENSLAND; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ADULT; CARDIOMYOPATHIES; EARLY DIAGNOSIS; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; NEW SOUTH WALES; PHENOTYPE; PREDICTIVE VALUE OF TESTS; QUEENSLAND; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84959419606     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2015-308494     Document Type: Article

References (17)

1. Zarate YA, Hopkin RJ. Fabry's disease. Lancet 2008; 372: 1427-35.
2. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003; 138: 338-46.
3. Patel MR, Cecchi F, Cizmarik M, et al. Cardiovascular events in patients with Fabry disease natural history data from the fabry registry. J Am Coll Cardiol 2011; 57: 1093-9.
4. Whybra C, Kampmann C, Krummenauer F, et al. The Mainz Severity Score Index: A new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 2004; 65: 299-307.
5. Beck M. The Mainz Severity Score Index (MSSI): Development and validation of a system for scoring the signs and symptoms of Fabry disease. Acta Paediatr Suppl 2006; 95: 43-6.
6. Moon JC, Sheppard M, Reed E, et al. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson 2006; 8: 479-82.
7. Moon JC, Sachdev B, Elkington AG, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003; 24: 2151-5.
8. Kramer J, Niemann M, Stork S, et al. Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease. Am J Cardiol 2014; 114: 895-900.
9. Weidemann F, Niemann M, Breunig F, et al. Long-Term effects of enzyme replacement therapy on Fabry cardiomyopathy: Evidence for a better outcome with early treatment. Circulation 2009; 119: 524-9.
10. Rosset A, Spadola L, Ratib O. OsiriX: An open-source software for navigating in multidimensional DICOM images. J Digit Imaging 2004; 17: 205-16.
11. Kozor R, Callaghan F, Tchan M, et al. A disproportionate contribution of papillary muscles and trabeculations to total left ventricular mass makes choice of cardiovascular magnetic resonance analysis technique critical in Fabry disease. J Cardiovasc Magn Reson 2015; 17: 22.
12. Maceira AM, Prasad SK, Khan M, et al. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2006; 8: 417-26.
13. Otsu N. A threshold selection method from gray-level histograms. Automatica 1975; 11: 23-7.
14. Niemann M, Liu D, Hu K, et al. Prominent papillary muscles in Fabry disease: A diagnostic marker? Ultrasound Med Biol 2011; 37: 37-43.
15. Niemann M, Herrmann S, Hu K, et al. Differences in Fabry cardiomyopathy between female and male patients: Consequences for diagnostic assessment. JACC Cardiovasc Imaging 2011; 4: 592-601.
16. Sechi A, Nucifora G, Piccoli G, et al. Myocardial fibrosis as the first sign of cardiac involvement in a male patient with Fabry disease: Report of a clinical case and discussion on the utility of the magnetic resonance in Fabry pathology. BMC Cardiovasc Disord 2014; 14: 86.
17. Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006; 8: 539-48.